BioXcel stock soars 17% as lead drug Igalmi starts to bring in revenue

Nov. 10, 2022 11:49 AM ETBioXcel Therapeutics, Inc. (BTAI)By: Ravikash, SA News Editor1 Comment

Business And Finance Concept Of A Bull Market Trend High Quality


BioXcel Therapeutics (NASDAQ:BTAI) stock rose ~17% on Thursday after the company's Q3 results which saw first ever sales of its lead drug Igalmi.

The company said net revenue of $137K in Q3 resulted from early product trial with limited market access. Due

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.